Kids B-LONG Phase III clinical trial for Alprolix (eftrenonacog alfa) as a treatment of haemophilia B is published in The Lancet Haematology.- SOBI + Bioverativ Inc.
Swedish Orphan Biovitrum AB (publ) (Sobi) and Bioverativ Inc. announced that results from the Kids B-LONG Phase III clinical trial, which studied Alprolix [eftrenonacog alfa, Coagulation Factor IX (Recombinant), Fc Fusion Protein] in previously-treated children with severe haemophilia B, were published in The Lancet Haematology. The primary outcome measure of the trial was development of inhibitors, and no patients treated with Alprolix in the study developed inhibitors. Treatment was generally well tolerated and resulted in low bleeding rates in participants, most of whom remained on once-weekly dosing during the study. The manuscript, entitled “Recombinant Factor IX Fc Fusion Protein in Children with Haemophilia B (Kids B-LONG): Results from a Multicentre, Non-Randomised Phase 3 Study,” was published in the February 2017 issue of The Lancet Haematology.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins